Since tumor-promoting inflammation is a typical feature of cancer, pioglitazone seems to be a promising agent due to its ability to decrease plasma C-reactive protein (CRP) levels by inhibiting interleukin 1 (IL1) expression. This evidence concerns the gene CRP and neoplasm.